Sysmex Corp (Sysmex) develops, manufactures and markets diagnostic instruments, reagents and related software products for analyzing samples of blood, urine and cells. It also offers devices and technologies for gene, cell and protein analysis. The company’s products are used in testing during health checkups, treatment and disease management. The company offers its products to medical institutions, universities, research institutions, national and other public hospitals.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sysmex is undertaking R&D initiatives to drive the growth of hematology and other existing domains by expanding its technological portfolio in the diagnostic field. The company is developing new technologies such as diagnostic and liquid biopsy technologies, refining personalized healthcare and testing, and enhancing the value of its testing and diagnostic solutions. The company is also leveraging its strengths for therapeutic fields, including medical robotics and regenerative and cellular medicine. It is focused on creating high-value testing technologies and promoting R&D to improve the quality of life globally. The R&D units of the compoany include the R&D, technology development, and product development divisions. The R&D support division contributes to the efficiency and quality of research across divisions. Additionally, the Sysmex R&D Center Europe GmbH in Hamburg, Germany, plays a role in ascertaining healthcare needs, conducting technology searches, developing new clinical applications, and building networks with medical and research institutions. The company has 23 R&D locations across nine countries. The company engages in major technology alliances through open innovation, M&A, and partnerships with universities, research institutions, and companies to create high added-value products and services. In FY2026, the company spent JPY29,162 million on its R&D, which as a percentage of revenue, stood at 5.8%.